# TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT

> **NCT04967495** · NA · UNKNOWN · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 171 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **PROCEDURE:** TACE combined with lenvatinib and iodion-125 seeds brachytherapy
- **PROCEDURE:** TACE combined with lenvatinib

## Key facts

- **NCT ID:** NCT04967495
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-09
- **Primary completion:** 2025-01-08
- **Final completion:** 2025-01-08
- **Target enrollment:** 171 (ESTIMATED)
- **Last updated:** 2023-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04967495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04967495, "TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04967495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*